The AVENIO ctDNA Expanded Kit is a next-generation sequencing (NGS) liquid biopsy assay with a 77 gene panel containing genes in U.S. National Comprehensive Cancer Network (NCCN) Guidelines1 and emerging cancer biomarkers. The Expanded Kit is a pan-cancer assay that’s specially optimized for lung cancer and colorectal cancer (CRC).
Accurate detection of all four classes of mutations with high sensitivity and specificity2,3
View performance data showing >96 to >99% sensitivity and >98 to >99% PPV for all four classes of mutations using the AVENIO ctDNA Expanded Kit.
The AVENIO ctDNA Expanded Kit is one of three assays in the AVENIO ctDNA assay portfolio. Learn more about the 17-gene AVENIO ctDNA Targeted Kit for guideline-driven tumor profiling or the 197-gene AVENIO ctDNA Surveillance Kit for longitudinal tumor burden monitoring.